

SUMMARY OF CHANGES:

INSTRUMENT NOS. 52 to 69 of 2020

Statements of Principles Nos. 52 to 69 of 2020 were signed by the Chairperson of the Repatriation Medical Authority (the Authority) on 28 August 2020. The day of commencement as specified in each of these Instruments is 28 September 2020.

These Instruments have been lodged and registered with the Federal Register of Legislation, pursuant to section 15G of the *Legislation Act 2003* (Legislation Act). In accordance with the Legislation Act, the Office of Parliamentary Counsel must generally deliver a legislative instrument for laying before each House of the Parliament within six sitting days of that House after the instrument is registered with the instrument's registered explanatory statement. The Instruments and the associated Explanatory Statements registered with the Federal Register of Legislation are available from http://www.legislation.gov.au.

Copies of each Instrument, the associated Explanatory Statement and a list of references relating to each Statement of Principles, are available in accordance with the *Veterans' Entitlements Act 1986* (the VEA), on written request from the RMA Secretariat.

The 'User Guide to the RMA Statements of Principles' explains the meaning and purpose of each section of the Statement of Principles template which commenced in 2015. This document is available on the Authority's website at http://www.rma.gov.au.

For further information contact:

The Registrar Repatriation Medical Authority GPO Box 1014 Brisbane Qld 4001

T +61 7 3815 9404 F +61 7 3815 9412 E info@rma.gov.au

4 September 2020

SUMMARY OF CHANGES

Title	Date of Commencement	ICD-10-AM Code
non-aneurysmal aortic atherosclerotic disease	28/09/2020	170.0
carotid artery disease	28/09/2020	I65.2, I70.8, I72.0, I77.0
renal artery atherosclerotic disease	28/09/2020	170.1
aplastic anaemia	28/09/2020	D61.1, D61.2, D61.3, D61.8
pure red cell aplasia	28/09/2020	D60
chloracne	28/09/2020	N/A
chronic pancreatitis	28/09/2020	K86.0, K86.1
malignant neoplasm of bone and articular cartilage	28/09/2020	C40, C41
S		
trochanteric bursitis and gluteal tendinopathy	28/09/2020	M70.6
	non-aneurysmal aortic atherosclerotic disease carotid artery disease renal artery atherosclerotic disease aplastic anaemia pure red cell aplasia chloracne chronic pancreatitis malignant neoplasm of bone and articular cartilage	non-aneurysmal aortic atherosclerotic disease carotid artery disease carotid artery atherosclerotic disease aplastic anaemia 28/09/2020 pure red cell aplasia 28/09/2020 chloracne 28/09/2020 chronic pancreatitis 28/09/2020 malignant neoplasm of bone and articular cartilage trochanteric bursitis and 28/09/2020

Note:

- The investigation concerning 'carotid arterial disease' has resulted in the determination of Statements of Principles concerning carotid artery disease.
- The investigation concerning 'aplastic anaemia' has resulted in the determination of Statements of Principles concerning aplastic anaemia and pure red cell aplasia.

SUMMARY OF CHANGES

52 & 53/2020 non-aneurysmal aortic atherosclerotic disease These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 7 May 2019 concerning *non-aneurysmal aortic atherosclerotic disease* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.

The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:

For RH SoP (Instrument No. 52/2020)

- adopting the latest revised Instrument format, which commenced in 2015;
- specifying a day of commencement for the Instrument in section 2;
- revising the definition of 'non-aneurysmal aortic atherosclerotic disease' in subsection 7(2);
- revising ICD-10-AM codes for 'non-aneurysmal aortic atherosclerotic disease' in subsection 7(3);
- revising the reference to 'ICD-10-AM code' in subsection 7(4);
- new factors in subsections 9(3) and 9(21) concerning being obese;
- revising the factors in subsections 9(4) and 9(22) concerning dyslipidaemia, by the inclusion of a note:
- new factors in subsections 9(5) and 9(23) concerning smoking of tobacco products, where smoking has not permanently ceased;
- new factors in subsections 9(6) and 9(24) concerning smoking of tobacco products, where smoking has permanently ceased;
- new factors in subsections 9(7) and 9(25) concerning exposure to second-hand smoke, where that exposure has not permanently ceased;
- new factors in subsections 9(8) and 9(26) concerning exposure to second-hand smoke, where that exposure has permanently ceased;
- new factors in subsections 9(10) and 9(28) concerning inability to undertake physical activity;
- new factors in subsections 9(11) and 9(29) concerning chronic kidney disease;
- revising the factors in subsections 9(13) and 9(31) concerning receiving ionising radiation, by the inclusion of a note;
- new factors in subsections 9(14) and 9(32) concerning inability to consume fruit and vegetables;
- new factors in subsections 9(15) and 9(33) concerning infection with human immunodeficiency virus or hepatitis C virus;
- new factors in subsections 9(17) and 9(35) concerning autoimmune disease;
- new factors in subsections 9(18) and 9(36) concerning having a clinically significant disorder of mental health as specified;
- deleting the factors concerning smoking of cigarettes or the equivalent thereof in other tobacco products, as these are now covered by the factors in subsections 9(5) and 9(23) concerning smoking of tobacco products, where smoking has not permanently ceased and the factors in subsections 9(6) and 9(24) concerning smoking of tobacco products, where smoking has permanently ceased;
- deleting the factors concerning being in an atmosphere with a visible tobacco smoke haze
 in an enclosed space, as these are now covered by the factors in subsections 9(7) and 9(25)
 concerning exposure to second-hand smoke, where that exposure has not permanently
 ceased and the factors in subsections 9(8) and 9(26) concerning exposure to second-hand
 smoke, where that exposure has permanently ceased;
- deleting the factors concerning chronic renal disease, as these are now covered by the factors in subsections 9(11) and 9(29) concerning chronic kidney disease;
- deleting the factors concerning having clinically significant depressive disorder, as these are now covered by the factors in subsections 9(18) and 9(36) concerning having a clinically significant disorder of mental health as specified;
- new definitions of 'abnormality of kidney structure or function', 'being exposed to second-hand smoke', 'being obese', 'BMI', 'chronic kidney disease', 'clinically significant disorder of mental health as specified', 'MET', 'MRCA', 'pack-year of tobacco products' and 'VEA' in Schedule 1 Dictionary;
- revising the definitions of 'dyslipidaemia' and 'relevant service' by the inclusion of a note in Schedule 1 Dictionary; and
- deleting the definitions of 'chronic renal disease', 'clinically significant',
 'hyperhomocysteinaemia' and 'pack-years of cigarettes, or the equivalent thereof in other
 tobacco products'.

For Bob Sob (Instrument No. 55/2020) adopting the laster trevised Instrument format, which commenced in 2015; specifying a date of effect for the Instrument in section 2; revising ICD-10-AM codes for 'non-aneutysmal aortic atheroselerotic disease' in subsection 7(2); revising the factors in subsections 9(1) and 9(14) concerning dyslipidaemia, by the inclusion of a note; revising the factors in subsections 9(3) and 9(14) concerning smoking of tobacco products, where smoking has not permanently ceased; new factors in subsections 9(3) and 9(15) concerning smoking of tobacco products, where smoking has permanently exased; new factors in subsections 9(3) and 9(17) concerning exposure to second-hand smoke, where that exposure has not permanently ceased; new factors in subsections 9(3) and 9(18) concerning exposure to second-hand smoke, where that exposure has not permanently ceased; new factors in subsections 9(3) and 9(20) concerning exposure to second-hand smoke, where that exposure has permanently ceased; new factors in subsections 9(3) and 9(20) concerning exposure to second-hand smoke, where that exposure has permanently ceased; new factors in subsections 9(3) and 9(20) concerning exposure to second-hand smoke, where that exposure has permanently ceased; everying the factors is subsections 9(3) and 9(18) concerning exposure to second-hand smoke, where that exposure has permanently ceased; everying the factors is subsections 9(3) and 9(18) concerning exposure to second-hand smoke, by the inclusion of a note; deleting the factors concerning smoking of eigerettes or the equivalent thereof in other tobacco products, as these are now covered by the factors in subsections 9(4) and 9(5) concerning smoking of tobacco products, where smoking has not permanently ceased and the factors in subsections 9(3) and 9(18) concerning smoking of tobacco products; every since the subsection 9(3) and 9(18) concerning smoking of bodacco products; every the subsection 9(3) and 9(18) concerning smoking of bodacco products; every facto	SUMMARY OF CHANGES				
specifying a data of effect for the Instrument in section 2; revising (ED-10-AM codes for non-ancuryman laorite atherosclerotic disease' in subsection 7(2); revising the factors in subsections 9(3) and 9(14) concerning dyslipidnemia, by the inclusion of a note: new factors in subsections 9(4) and 9(15) concerning myslipidnemia, by the inclusion of a note: new factors in subsections 9(4) and 9(15) concerning smoking of tobacco products, where smoking has permanently ceased; new factors in subsections 9(3) and 9(14) concerning exposure to second-hand smoke, where smoking has permanently ecased; new factors in subsections 9(7) and 9(16) concerning exposure to second-hand smoke, where that exposure has not permanently ceased; new factors in subsections 9(7) and 9(18) concerning exposure to second-hand smoke, where that exposure has permanently ceased; new factors in subsections 9(7) and 9(18) concerning exposure to second-hand smoke, where that exposure has permanently ceased; new factors in subsections 9(9) and 9(20) concerning exposure to second-hand smoke, where that exposure has permanently ceased; new factors in subsections 9(9) and 9(20) concerning receiving ionising radiation, by the inclusion of a note; deleting the factors in subsections 9(11) and 9(22) concerning receiving ionising radiation, by the inclusion of a note; deleting the factors in subsections 9(3) and 9(16) concerning smoking of tobacco products, where smoking has not permanently ceased and the factors in subsections 9(3) and 9(16) concerning smoking of tobacco products, where smoking has not permanently ceased and the factors in subsections 9(3) and 9(16) concerning smoking of tobacco products, where smoking has permanently ceased; new definitions of device of the subsection 9(2) and 9(2) concerning tobacco products, where smoking has permanently ceased; new determinent of the subsection 9(3) and 9(3) and 9(3) concerning exposure of tobacco products, where smoking has permanently ceased; new factors in subsec			For BoP SoP (Instrument No. 53/2020)		
revising the definition of 'non-ancurysmal aortic atheroselerotic disease' in subsection 7(3); revising the Febreace to TCD-10-AM code' in subsection 7(4); revising the feators in subsections 9(3) and 9(14) concerning dyslipidaemia, by the inclusion of a note: new factors in subsections 9(4) and 9(15) concerning smoking of tobacco products, where smoking has not permanently ceased; new factors in subsections 9(5) and 9(16) concerning exposure to second-hand smoke, where that exposure has not permanently ceased; new factors in subsections 9(5) and 9(16) concerning exposure to second-hand smoke, where that exposure has not permanently ceased; new factors in subsections 9(7) and 9(18) concerning exposure to second-hand smoke, where that exposure has not permanently ceased; new factors in subsections 9(7) and 9(20) concerning exposure to second-hand smoke, where that exposure has not permanently ceased; new factors in subsections 9(7) and 9(20) concerning exposure to second-hand smoke, where that exposure has not permanently ceased; new factors in subsections 9(9) and 9(20) concerning exposure to second-hand smoke, where factors in subsections 9(9) and 9(20) concerning exposure to second-hand smoke, of the factors in subsections 9(9) and 9(20) concerning exposure to second-hand smoke, of the factors in subsections 9(9) and 9(15) concerning smoking of indexed products, where smoking has permanently ceased, and the factors in subsections 9(5) and 9(16) concerning smoking of tobacco products, where smoking has permanently ceased. new definitions of 'dyslipidaemia', and 'relevant service' by the inclusion of a note in Schedule 1 - Dictionary; revising the definitions of 'dyslipidaemia', and 'relevant service' by the inclusion of a note in Schedule 1 - Dictionary; revising the definitions of 'dyslipidaemia', and 'relevant service' by the inclusion of a note in Schedule 1 - Dictionary; revising the definitions of 'dyslipidaemia', and 'relevant service' by the incl					
revising (CD-10-AM codes for non-aneurysmal aortic atherosclerotic diseases' in subsection 7(3); revising the reference to "ICD-10-AM code' in subsection 7(4); revising the factors in subsections 9(3) and 9(14) concerning dyslipidaemia, by the inclusion of a note; new factors in subsections 9(4) and 9(15) concerning smoking of tobacco products, where smoking has permanently ecased; new factors in subsections 9(5) and 9(16) concerning exposure to second-hand smoke, where that exposure has not permanently ceased; new factors in subsections 9(7) and 9(17) concerning exposure to second-hand smoke, where that exposure has not permanently ceased; new factors in subsections 9(7) and 9(18) concerning exposure to second-hand smoke, where that exposure has not permanently ceased; new factors in subsections 9(7) and 9(18) concerning receiving foinising radiation, by the inclusion of a note; deleting the factors concerning smoking of cigarettes or the equivalent thereof in other tobacco products, as these are now covered by the factors in subsections 9(4) and 9(15) concerning smoking in the factors in subsections 9(4) and 9(15) concerning smoking of induces products, where smoking has permanently ceased. • new definitions of bancumality of kidney structure or function, being exposed to second hand smoke, 'chronic kidney disease,' MRCA', 'pack-year of tobacco products, where smoking has permanently ceased. • new definitions of 'abnormality of kidney structure or function,' being exposed to second hand smoke,' chronic kidney disease,' MRCA', 'pack-year of tobacco products,' and deleting the definitions of 'hyperhomocysteinaemia' and 'pack-years of cigarettes, or equivalent thereof in other tobacco products. • The determining of these Instruments finalises the investigation in relation to non-aneutrysmal aortic atherosclerotic disease as advertised in the Government Notices Gazette of 20 october of 'hyperhomocysteinaemia' and 'pack-years of cigarettes, or equivalent thereof in other tob					
7(3): revising the factors in subsections 9(3) and 9(14) concerning dyslipidaemia, by the inclusion of a note; new factors in subsections 9(4) and 9(15) concerning smoking of tobacco products, where smoking has not permanently ceased; new factors in subsections 9(5) and 9(16) concerning smoking of tobacco products, where smoking has permanently ceased; new factors in subsections 9(5) and 9(17) concerning exposure to second-hand smoke, where that exposure has not permanently ceased; new factors in subsections 9(7) and 9(18) concerning exposure to second-hand smoke, where that exposure has permanently veased; new factors in subsections 9(7) and 9(18) concerning receiving ionising radiation, by the inclusion of a note; electing the factor in subsections 9(10) and 9(22) concerning receiving ionising radiation, by the inclusion of a note; electing the factors of subsections 9(10) and 9(22) concerning receiving ionising radiation, by the inclusion of a note; electing the factors of subsections 9(10) and 9(22) concerning receiving ionising radiation, by the inclusion of a note; electing the factors of subsections 9(7) and 9(16) concerning smoking of consecution of tobacco products, at lases are now covered by the factors in subsections 9(4) and 9(15) and the factors in subsections 9(4) and 9(15) and the factors in subsections 9(6) and 9(16) concerning smoking of lobacco products, and the factors in subsections 9(6) and 9(16) concerning smoking of lobacco products and VEA/ in Schedule 1 - Dictionary; evidence in the definitions of subsections 9(8) and 9(16) concerning around in the inclusion of a note in Schedule 1 - Dictionary; and definitions of disperimental subsection 19(3) and 9(3) electing the definitions of subsection 19(3) and 9(3) electing the definitions of a note in Schedule 1 - Dictionary; and definitions of subsection 19(3) and 9(3) election 19(4) and 9(3) electing the definitions of subsection 19(5) and 9(3) election 19(4) and 9(4) electing the subsection 19(5) and 9(4) electing the lactor in s					
Pervising the reference to "ICD-10-AM code" in subsection 7(4): Pervising the factors in subsections 9(3) and 9(14) concerning dyslipidsemia, by the inclusion of a note; new factors in subsections 9(4) and 9(15) concerning smoking of tobacco products, where smoking has not permanently ceased; new factors in subsections 9(6) and 9(15) concerning exposure to second-hand smoke, where that exposure has not permanently ceased; new factors in subsections 9(7) and 9(18) concerning exposure to second-hand smoke, where that exposure has permanently ceased; new factors in subsections 9(7) and 9(18) concerning chronic kidney disease; revising the factors in subsections 9(7) and 9(18) concerning receiving ionising radiation, by the inclusion of a note; deleting the factors concerning smoking of cigarettes or the equivalent thereof in other tobacco products, as these are now covered by the factors in subsections 9(19) and 9(15) concerning smoking of baucco products, where smoking has permanently ceased; new definitions of abnormality of kidney structure or function,* being exposed to where smoking has permanently ceased; new definitions of abnormality of kidney structure or function,* being exposed to Auch in Schedule 1 - Dictionary; revising the definitions of 'dyslipidaemia', and 'relevant service' by the inclusion of a note in Schedule 1 - Dictionary; revising the definitions of 'dyslipidaemia', and 'relevant service' by the inclusion of a note in Schedule 1 - Dictionary; revising the definitions of 'dyslipidaemia', and 'relevant service' by the inclusion of a note in Schedule 1 - Dictionary; revising the definitions of 'dyslipidaemia', and 'relevant service' by the inclusion of a note in Schedule 1 - Dictionary; revising the definition of 'dyslipidaemia', and 'relevant service' by the inclusion of a note in Schedule 1 - Dictionary; revising the definition of 'dyslipidaemia', and 'relevant service' by the inclusion of a note in Schedule 1 - Dictionary; revising the definition of 'dyslipidaemia', and 'rel			· ·		
revising the factors in subsections 9(3) and 9(14) concerning dyslipidaemia, by the inclusion of a note; new factors in subsections 19(3) and 9(15) concerning smoking of tobacco products, where smoking has not permanently ceased; new factors in subsections 9(5) and 9(16) concerning smoking of tobacco products, where smoking has permanently ceased; new factors in subsections 9(7) and 9(18) concerning exposure to second-hand smoke, where that exposure has not permanently ceased; new factors in subsections 9(7) and 9(18) concerning exposure to second-hand smoke, where that exposure has permanently ceased; new factors in subsections 9(7) and 9(18) concerning exposure to second-hand smoke, where that exposure has permanently ceased; new factors in subsections 9(7) and 9(18) concerning receiving ionising radiation, by the inclusion of a note in obacco products, as these are now covered by the factors in subsections 9(4) and 9(15) concerning smoking of tobacco products, where smoking has not permanently ceased; deleting the factors concerning smoking of cigarettes or the equivalent thereof in other tobaccor products, where smoking has permanently ceased; new definitions of short in subsections 9(5) and 9(16) concerning smoking of tobacco products, where smoking has permanently ceased; new definitions of short in subsections of the subsect of the subs					
of a note; new factors in subsections 9(4) and 9(15) concerning smoking of tobacco products, where smoking has not permanently ceased; new factors in subsections 9(5) and 9(16) concerning smoking of tobacco products, where smoking has permanently ceased; new factors in subsections 9(5) and 9(17) concerning exposure to second-hand smoke, where that exposure has not permanently ceased; new factors in subsections 9(7) and 9(18) concerning exposure to second-hand smoke, where that exposure has permanently ceased; new factors in subsections 9(7) and 9(18) concerning receiving ionising radiation, by the inclusion of a note; electing the factors concerning smoking of cigarettes or the equivalent thereof in other tobacco products, sa these are now covered by the factors in subsections 9(4) and 9(15) concerning smoking of obacco products, where smoking has not permanently ceased; new definitions of abnormality of kidney structure or function!, being exposed to second-hand smoke, 'chronic kidney disease,' MRCA', 'pack-year of tobacco products, where smoking has permanently ceased; new definitions of 'abnormality of kidney structure or function!,' being exposed to second-hand smoke, 'chronic kidney disease,' MRCA', 'pack-year of tobacco products, where smoking the definitions of 'dyslipidemia', and 'relevant service' by the inclusion of a note in Schedule 1 - Dictionary; revising the definitions of 'dyslipidemia', and 'relevant service' by the inclusion of a note in Schedule 1 - Dictionary; and deleting the definitions of 'dyslipidemia', and 'relevant service' by the inclusion of a note in Schedule 1 - Dictionary; revising the definitions of 'hyperhomocysteinaemia' and 'pack-years of cigarettes, equivalent thereof in other tobacco products.' The determining of these Instruments finalises the investigation in relation to non-neurysmal aorie admiration of the Notices Gazette of 20 October 2019 concerning carould arterial disease in secondance with section 1960 of the VEA. The investigation involved an examinatio					
smoking has not permanently ceased; new factors in subsections 9(5) and 9(16) concerning smoking of tobacco products, where smoking has permanently ceased; new factors in subsections 9(6) and 9(17) concerning exposure to second-hand smoke, where that exposure has not permanently ceased; new factors in subsections 9(7) and 9(18) concerning exposure to second-hand smoke, where that exposure has permanently ceased; new factors in subsections 9(9) and 9(20) concerning chronic kidney disease; revising the factors in subsections 9(1) and 9(20) concerning receiving ionising radiation, by the inclusion of a note; deleting the factors concerning smoking of cigarettes or the equivalent thereof in other tobacco products, as these are now covered by the factors in subsections 9(1) and 9(15) concerning smoking of tobacco products, where smoking has not permanently ceased and the factors in subsections 9(5) and 9(16) concerning smoking of tobacco products, where smoking has permanently ceased; new definitions of 'abnormality of kidney structure or function', being exposed to second-hand smoke', chronic kidney diseases,' MRCA', pack-year of tobacco products' and 'VEA' in Schedule 1- Dictionary; revising the definitions of 'thylenthemia', and 'relevant service' by the inclusion of a note in Schedule 1- Dictionary; revising the definitions of 'thylenthemia', and 'relevant service' by the inclusion of a note in Schedule 1- Dictionary; revising the terminant of 'thylenthemia', and 'relevant service' by the inclusion of a note in Schedule 1- Dictionary; revising a darie atheresseleroid: disease as advertised in the Government Notices Gazette of TMay 2019. These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of TMay 2019. These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 290 October 2019 concerning curotid artery disease in accordance with section 1966 of the VEA. The investigation involved an examination o					
• new factors in subsections 9(5) and 9(16) concerning smoking of tobacco products, where smoking has permanently ceased; • new factors in subsections 9(6) and 9(17) concerning exposure to second-hand smoke, where that exposure has not permanently ceased; • new factors in subsections 9(7) and 9(18) concerning exposure to second-hand smoke, where that exposure has permanently ceased; • new factors in subsections 9(0) and 9(20) concerning chronic kidney disease; • revising the factors in subsections 9(11) and 9(22) concerning receiving ionising radiation, by the inclusion of a note; • deleting the factors concerning smoking of eigarettes or the equivalent thereof in other tobacco products, as these are now covered by the factors in subsections 9(4) and 9(15) concerning smoking of tobacco products, where smoking has not permanently ceased and the factors in subsections 9(3) and 9(16) concerning smoking of tobacco products, where smoking has permanently ceased; • new definitions of abnormality of kidney structure or function', being exposed to second-hand smoke', chronic kidney disease,' MRCA', pack-year of tobacco products' in Schedule 1 - Dictionary; • revising the definitions of 'dyslipidaemia', and 'relevant service' by the inclusion of a note in Schedule 1 - Dictionary; and • deleting the definitions of 'dyslipidaemia', and 'relevant service' by the inclusion of a note in Schedule 1 - Dictionary; and • deleting the definitions of 'dyslipidaemia', and relevant service' by the inclusion of a note in Schedule 1 - Dictionary; and • deleting the definitions of 'dyslipidaemia', and relevant service' by the inclusion of a note in Schedule 1 - Dictionary; and • deleting the definitions of 'dyslipidaemia', and relevant service' by the inclusion of a note; • revising the definition of 'dyslipidaemia', and relevant service' by the inclusion of a note; • second of the s			• new factors in subsections 9(4) and 9(15) concerning smoking of tobacco products, where		
smoking has permanently ceased; new factors in subsections 9(6) and 9(17) concerning exposure to second-hand smoke, where that exposure has not permanently ceased; new factors in subsections 9(7) and 9(18) concerning exposure to second-hand smoke, where that exposure has permanently ceased; new factors in subsections 9(9) and 9(20) concerning chronic kidney disease; evising the factors in subsections 9(1) and 9(22) concerning receiving ionising radiation, by the inclusion of a note; deleting the factors concerning smoking of cigarettes or the equivalent thereof in other tobacco products, as these are now covered by the factors in subsections 9(4) and 9(15) concerning smoking of tobacco products, where smoking has not permanently ceased, new definitions of abnormality of kidney structure or function', 'being exposed to second-hand smoke', 'chronic kidney disease', 'MRCA', 'pack-year of tobacco products' and 'VEA' in Schedule 1- Dictionary; revising the definitions of 'dyslipidaemia', and 'relevant service' by the inclusion of a note in Schedule 1- Dictionary; and deleting the definitions of 'hyperhomoeysteinaemia' and 'pack-years of cigarettes, or equivalent thereof in other tobacco products'. The determining of these Instruments finalises the investigation in relation to non-anenysmal another atherosclerotic disease as advertised in the Government Notices Gazette of 70 tobac 2019 concerning carotid arterial disease in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence on wariable to the Authority, including the sound medical-scientific evidence in this previously considered. The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include: For RH SoP (Instrument No. 54/2020) adopting the latest revised Instrument format, which commenced in 2015; specifying a day of commencement for the Instrument accidence of the second particul					
• new factors in subsections 9(6) and 9(17) concerning exposure to second-hand smoke, where that exposure has permanently ceased; • new factors in subsections 9(7) and 9(18) concerning exposure to second-hand smoke, where that exposure has permanently ceased; • new factors in subsections 9(0) and 9(20) concerning exposure to second-hand smoke, where that exposure has permanently ceased; • revising the factors in subsections 9(11) and 9(22) concerning receiving ionising radiation, by the inclusion of a note; • deleting the factors concerning smoking of cigarettes or the equivalent thereof in other tobace oproducts, as these are now covered by the factors in subsections 9(4) and 9(15) concerning smoking of tobacco products, where smoking has permanently ceased; • new definitions of inhormality of life) concerning smoking of tobacco products, where smoking has permanently ceased; • new definitions of inhormality of life) concerning smoking of tobacco products, where smoking has permanently ceased; • new definitions of inhormality of kidney structure or function!, being exposed to second-hand smoke', 'chronic kidney disease', 'MRCA', 'pack-year of tobacco products' in Schedule 1 - Dictionary; • revising the definitions of 'dyslipidaemia', and 'relevant service' by the inclusion of a note in Schedule 1 - Dictionary; • revising the definitions of 'dyslipidaemia', and 'relevant service' by the inclusion of a note in Schedule 1 - Dictionary; • revising the definitions of 'dyslipidaemia', and 'relevant service' by the inclusion of a note; • revising and anote atherosclerotic disease as advertised in the Government Notices Gazette of 29 October 2019 concerning carotid arterial disease in accordance with section 194 of 194 permanents of the sound medical-scientific evidence in has previously considered. These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 29 October 2019 concerning carotid arterial disease in accorda					
where that exposure has not permanently ceased; new factors in subsections 9(7) and 9(18) concerning exposure to second-hand smoke, where that exposure has permanently ceased; new factors in subsections 9(9) and 9(20) concerning chronic kidney disease; revising the factors in subsections 9(11) and 9(22) concerning receiving ionising radiation, by the inclusion of a note; deleting the factors concerning smoking of cigarettes or the equivalent thereof in other tobacco products, as these are now covered by the factors in subsections 9(4) and 9(15) concerning smoking of tobacco products, where smoking has not permanently ceased; where the factors in subsections 9(5) and 9(16) concerning smoking of tobacco products, where smoking has permanently ceased; new definitions of 'abnormality of kidney structure or function', 'being exposed to second-hand smoke,' chronic kidney disease', 'MRCA', 'pack-year of tobacco products' and 'VEA' in Schedule 1 - Dictionary; revising the definitions of 'dyslipidaemia', and 'relevant service' by the inclusion of a note in Schedule 1 - Dictionary; revising the definitions of 'hyperhomocysteinaemia' and 'pack-years of cigarettes, or equivalent thereof in other tobacco products'. The determining of these Instruments finalises the investigation in relation to non-aneutymand aurite atherosclerotic disease as advertised in the Government Notices Gazette of 7 May 2019. These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 20 clother 2019 concerning carontal arterial disease in accordance with section 1966 of the VFA. The investigation involved an examination of the sound medical-scientific evidence on wavailable to the Authority, including the sound medical-scientific evidence on wavailable to the Authority, including the sound medical-scientific evidence on wavailable to the Authority, including the sound medical-scientific evidence on wavailable to the Authority, including the sound medical-scientific evidence now available t					
new factors in subsections 9(7) and 9(18) concerning exposure to second-hand smoke, where that exposure has permanently ceased; new factors in subsections 9(9) and 9(20) concerning freceiving ionising radiation, by the inclusion of a note; deleting the factors concerning smoking of cigarettes or the equivalent thereof in other tobacco products, as these are now covered by the factors in subsections 9(4) and 9(15) concerning smoking of tobacco products, where smoking has not permanently ceased, and the factors in subsections 9(5) and 9(16) concerning smoking of tobacco products, where smoking has permanently ceased, and the factors in subsections 9(5) and 9(16) concerning smoking of tobacco products, where smoking has permanently ceased, and the factors in subsections 9(5) and 9(16) concerning smoking of tobacco products, where smoking has permanently ceased, and the factors in subsections 9(5) and 9(16) concerning smoking of tobacco products, where smoking has not permanently ceased, and the factors in subsection is subsection of a note in Schedule 1 - Dictionary; revising the definitions of 'dyspitolacmia', and 'relevant service' by the inclusion of a note in Schedule 1 - Dictionary; and determining of these Instruments finalises the investigation in relation to non-anautymal aurit catherosclerotic disease as advertised in the Government Notices Gazette of 7 May 2019. The determining of these Instruments finalises the investigation in relation to non-anautymal aurit catherosclerotic disease as advertised in the Government Notices Gazette of 79 October 2019 concerning carvoid arterial disease in accordance with Notices Gazette of 79 October 2019 concerning carvoid arterial disease in accordance with Notices Gazette of 79 October 2019 concerning carvoid arterial disease in accordance with Notices Gazette of 79 October 2019 concerning carvoid arterial disease in accordance with Notices Gazette of 79 October 2019 concerning carvoid arterial disease in accordance with Notices Gazette of 79 October					
where that exposure has permanently ceased; new factors in subsections 9(9) and 9(20) concerning chronic kidney disease; revising the factors in subsections 9(11) and 9(22) concerning receiving ionising radiation, by the inclusion of a note; deleting the factors concerning smoking of cigarettes or the equivalent thereof in other tobacco products, as these are now covered by the factors in subsections 9(4) and 9(15) concerning smoking of tobacco products, where smoking has permanently ceased and the factors in subsections 9(5) and 9(16) concerning smoking of tobacco products, where smoking has permanently ceased; new definitions of 'abnormality of kidney structure or function', being exposed to second-hand smoke, 'chronic kidney disease,' MRCA', 'pack-year of tobacco products' and 'VEA' in Schedule 1 - Dictionary; and deleting the definitions of 'dyslipidaemia', and 'relevant service' by the inclusion of a note in Schedule 1 - Dictionary; and deleting the definitions of 'hyperhomocysteinaemia' and 'pack-years of cigarettes, or equivalent thereof in other tobacco products'. The determining of these Instruments finalises the investigation in relation to non-anautysmal aortic atherosclerotic disease as advertised in the Government Notices Gazette of T May 2019. These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of T Suppersonation of the Suppersonation of Suppersonation of Suppersonation of Suppersonation of Supp					
• revising the factors in subsections 9(11) and 9(22) concerning receiving ionising radiation, by the inclusion of a note; • deleting the factors concerning smoking of cigarettes or the equivalent thereof in other tobacco products, as these are now covered by the factors in subsections 9(4) and 9(15) concerning smoking of tobacco products, where smoking has permanently ceased and the factors in subsections 9(5) and 9(16) concerning smoking of tobacco products, where smoking has permanently ceased; • new definitions of 'abnormality of kidney structure or function', 'being exposed to second-hand smoke', 'chronic kidney disease', 'MRCA', 'pack-year of tobacco products' and 'VFA' in Schedule 1 - Dictionary; • revising the definitions of 'hyperhomocysteinaemia' and 'pack-years of cigarettes, or equivalent thereof in other tobacco products'. The determining of these Instruments finalises the investigation in relation to non-aneurysmal aortic atherosclerofic disease as advertised in the Government Notices Gazette of 7 May 2019. These Instruments result from an investigation notified by the Authority in the Government Notices (Gazette of 7 May 2019). These Instruments result from an investigation involved an examination of the sound medical-scientific evidence in the spreviously considered. The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include: For RH Sop (Instrument No. 5472020) adopting the latest revised Instrument format, which commenced in 2015; specifying a day of commencement for the Instrument in section 2; revising the Theorems of the condition from 'carotid atterial disease' to 'carotid artery disease'; new definition of 'carotid artery disease' in subsection 7(2); revising the Theorems of the condition from 'carotid artery disease' in subsection 7(3); revising the Theorems of the condition from 'carotid artery disease' in subsection 7(4); new factors in subsections 9(5) and 9(30) concer					
by the inclusion of a note; deleting the factors concerning smoking of cigarettes or the equivalent thereof in other tobacco products, as these are now covered by the factors in subsections 9(4) and 9(15) concerning smoking of tobacco products, where smoking has not permanently ceased and the factors in subsections 9(5) and 9(16) concerning smoking of tobacco products, where smoking has permanently ceased; new definitions of 'ubnormality of kidney structure or function', 'being exposed to second-hand smoke', 'chronic kidney disease', 'MRCA', 'pack-year of tobacco products' in Schedule 1 - Dictionary; revising the definitions of 'dyslipidaemia', and 'relevant service' by the inclusion of a note in Schedule 1 - Dictionary; and deleting the definitions of 'hyperhomocysteinaemia' and 'pack-years of cigarettes, or equivalent thereof in other tobacco products'. The determining of these Instruments finalises the investigation in relation to non-aneurysmal aortic atherosclerotic disease as advertised in the Government Notices Gazette of 7 May 2019. These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 29 October 2019 concerning carotid arterial disease in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence in has previously considered. The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include: For RH SoP (Instrument No. 54/2020) adopting the latest revised Instrument format, which commenced in 2015; specifying a day of commencement for the Instrument in section 2; revising the name of the condition from 'carotid arterial disease' to 'carotid artery disease'; new definition of 'carotid artery disease' in subsection 7(2); revising the factors in subsections 9(3) and 9(28) concerning dyslipidaemia, by the inclusion of a note; new factors in subsections 9(3) and 9(30) concerning moki			• new factors in subsections 9(9) and 9(20) concerning chronic kidney disease;		
deleting the factors concerning smoking of cigarettes or the equivalent thereof in other tobacco products, as these are now covered by the factors in subsections 9(4) and 9(15) concerning smoking of tobacco products, where smoking has permanently ceased and the factors in subsections 9(5) and 9(16) concerning smoking of tobacco products, where smoking has permanently ceased; new definitions of 'abnormality of kidney structure or function', 'being exposed to second-hand smoke', 'chronic kidney disease', 'MRCA', 'pack-year of tobacco products' and 'VEA' in Schedule 1 - Dictionary; revising the definitions of 'dyslipidaemia', and 'relevant service' by the inclusion of a note in Schedule 1 - Dictionary; and deleting the definitions of 'hyperhomocysteinaemia' and 'pack-years of cigarettes, or equivalent thereof in other tobacco products'. The determining of these Instruments finalises the investigation in relation to non-ameurysmal aortic atherosclerotic disease as advertised in the Government Notices Gazette of 7 May 2019. These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 29 October 2019 concerning caroutd arrerial disease in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence in thas previously considered. The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include: For RH SoP (Instrument No. 542020) adopting the latest revised Instrument format, which commenced in 2015; specifying a day of commencement for the Instrument in section 2; revising the reference to 'ICD-10-AM code' in subsection 7(2); revising the reference to 'ICD-10-AM code' in subsection 7(3); revising the reference to 'ICD-10-AM code' in subsection 7(4); new factors in subsections 9(3) and 9(28) concerning moking of tobacco products, where smoking has not permanently ceased; new factors was bussectio					
tobacco products, as these are now covered by the factors in subsections 9(4) and 9(15) concerning smoking of tobacco products, where smoking has not permanently ceased and the factors in subsections 9(5) and 9(16) concerning smoking of tobacco products, where smoking has permanently ceased; • new definitions of 'abnormality of kidney structure or function', 'being exposed to second-hand smoke', 'chronic kidney disease', 'MRCA', 'pack-year of tobacco products' and 'VEA' in Schedule 1 - Dictionary; • revising the definitions of 'dyslipidaemia', and 'relevant service' by the inclusion of a note in Schedule 1 - Dictionary; and • deleting the definitions of 'hyperhomocysteinaemia' and 'pack-years of cigarettes, or equivalent thereof in other tobacco products'. The determining of these Instruments finalises the investigation in relation to non-aneurysmal aortic atherosclerotic disease as advertised in the Government Notices Gazette of 7 May 2019. These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 29 October 2019 concerning carotid arterial disease in accordance with section 1966 of the VEA. The investigation involved an examination of the sound medical-scientific evidence in has previously considered. The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include: For RH SoP (Instrument No. 54/2020) • adopting the latest revised Instrument format, which commenced in 2015; • specifying a day of commencement for the Instrument in section 2; • revising the name of the condition from 'carotid arterial disease' to 'carotid artery disease'; • new definition of 'carotid artery disease' in subsection 7(3); • revising the reference to TCD-10-AM code' for carotid artery disease' in subsection 7(3); • revising the reference to TCD-10-AM code' in subsection 7(4); • new factors in subsections 9(3) and 9(28) concerning smoking of tobacco products, where smo					
concerning smoking of tobacco products, where smoking has not permanently ceased and the factors in subsections 9(5) and 9(16) concerning smoking of tobacco products, where smoking has permanently ceased; • new definitions of 'abnormality of kidney structure or function', 'being exposed to second-hand smoke', 'chronic kidney disease', 'MRCA', 'pack-year of tobacco products' and 'VEA' in Schedule 1 - Dictionary; • revising the definitions of 'dyslipidaemia', and 'relevant service' by the inclusion of a note in Schedule 1 - Dictionary; and • deleting the definitions of 'hyperhomocysteinaemia' and 'pack-years of cigarettes, or equivalent thereof in other tobacco products'. The determining of these Instruments finalises the investigation in relation to non-aneutrysmal aortic atherosclerotic disease as advertised in the Government Notices Gazette of 7 May 2019. These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 29 October 2019 concerning carotid arterial disease in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence it has previously considered. The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include: For RH SoP (Instrument No. 54/2020) • adopting the latest revised Instrument format, which commenced in 2015; • specifying a day of commencement for the Instrument in section 2; • revising the mame of the condition from 'carotid arterial disease' to 'carotid artery disease'; • new definition of 'carotid artery disease' in subsection 7(3); • revising the reference to 'ICD-10-AM code' in subsection 7(3); • revising the factors in subsections 9(3) and 9(28) concerning being obese; • revising the factors in subsections 9(4) and 9(29) concerning dyslipidaemia, by the inclusion of a note; • new factors in subsections 9(6) and 9(31) concerning exposure to second-hand smoke, where t					
the factors in subsections 9(5) and 9(16) concerning smoking of tobacco products, where smoking has permanently ceased; • new definitions of 'abnormality of kidney structure or function', 'being exposed to second-hand smoke', 'chronic kidney disease', 'MRCA', 'pack-year of tobacco products' and 'VEA' in Schedule 1 - Dictionary; and • deleting the definitions of 'dyslipidaemia', and 'relevant service' by the inclusion of a note in Schedule 1 - Dictionary; and • deleting the definitions of 'hyperhomocysteinaemia' and 'pack-years of eigarettes, or equivalent thereof in other tobacco products'. The determining of these Instruments finalises the investigation in relation to non-aneurysmal aortic atherosclerotic disease as advertised in the Government Notices Gazette of 7 May 2019. These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 29 October 2019 concerning carotid arterial disease in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence it has previously considered. The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include: For RH SoP (Instrument No. 54/2020) • adopting the latest revised Instrument format, which commenced in 2015; • specifying a day of commencement for the Instrument in section 2; • revising the name of the condition from 'carotid arterial disease' to 'carotid artery disease'; • new definition of 'carotid artery disease' in subsection 7(2); • revising the reference to 'ICD-10-AM code' in subsection 7(3); • revising the ference to 'ICD-10-AM code' in subsection 7(4); • new factors in subsections 9(6) and 9(3) concerning smoking of tobacco products, where smoking has not permanently ceased; • new factors in subsections 9(6) and 9(31) concerning smoking of tobacco products, where smoking has permanently ceased; • new factors in subsections 9(6) and 9(31) conce					
smoking has permanently ceased; new definitions of 'abnormality of kidney structure or function', 'being exposed to second-hand smoke', 'chronic kidney disease', 'MRCA', 'pack-year of tobacco products' and 'VEA' in Schedule 1 - Dictionary; revising the definitions of 'dyslipidaemia', and 'relevant service' by the inclusion of a note in Schedule 1 - Dictionary; and deleting the definitions of 'hyperhomocysteinaemia' and 'pack-years of cigarettes, or equivalent thereof in other tobacco products'. The determining of these Instruments finalises the investigation in relation to non-aneurysmal aortic atherosclerotic disease as advertised in the Government Notices Gazette of 7 May 2019. These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 29 October 2019 concerning carotid arterial disease in accordance with Section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence in has previously considered. The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include: For RH SoP (Instrument No. 54/2020) adopting the latest revised Instrument format, which commenced in 2015; specifying a day of commencement for the Instrument in section 2; revising the name of the condition from 'carotid arterial disease' to 'carotid artery disease'; new definition of 'carotid artery disease' in subsection 7(2); revising ICD-10-AM codes for 'carotid artery disease' in subsection 7(3); revising the reference to 'ICD-10-AM code' in subsection 7(4); new factors in subsections 9(3) and 9(28) concerning being obese; revising the factors in subsections 9(4) and 9(29) concerning dyslipidaemia, by the inclusion of a note; new factors in subsections 9(5) and 9(30) concerning smoking of tobacco products, where smoking has not permanently ceased; new factors in subsections 9(3) and 9(31) concerning exposure to second-hand smoke, where that exp					
hand smoke, 'chronic kidney disease', 'MRCA', 'pack-year of tobacco products' and 'VEA' in Schedule 1 - Dictionary; • revising the definitions of 'dyslipidaemia', and 'relevant service' by the inclusion of a note in Schedule 1 - Dictionary; and • deleting the definitions of 'hyperhomocysteinaemia' and 'pack-years of cigarettes, or equivalent thereof in other tobacco products'. The determining of these Instruments finalises the investigation in relation to non-aneurysmal aortic atherosclerotic disease as advertised in the Government Notices Gazette of 7 May 2019. These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 29 October 2019 concerning carotid arterial disease in accordance with section 1966 of the VEA. The investigation involved an examination of the sound medical-scientific evidence in thas previously considered. The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include: For RH SoP (Instrument No. 54/2020) • adopting the latest revised Instrument format, which commenced in 2015; • specifying a day of commencement for the Instrument in section 2; • revising the name of the condition from 'carotid arterial disease' to 'carotid artery disease'; • new definition of 'carotid artery disease' in subsection 7(2); • revising tCD-10-AM codes for 'carotid artery disease' in subsection 7(3); • revising the reference to 'ICD-10-AM code' in subsection 7(3); • revising the factors in subsections 9(3) and 9(28) concerning being obese; • revising the factors in subsections 9(3) and 9(28) concerning smoking of tobacco products, where smoking has not permanently ceased; • new factors in subsections 9(5) and 9(31) concerning smoking of tobacco products, where smoking has permanently ceased; • new factors in subsections 9(6) and 9(31) concerning exposure to second-hand smoke, where that exposure has permanently ceased; • new factors in subsections 9(8) and					
in Schedule 1 - Dictionary; revising the definitions of 'dyslipidaemia', and 'relevant service' by the inclusion of a note in Schedule 1 - Dictionary; and deleting the definitions of 'hyperhomocysteinaemia' and 'pack-years of cigarettes, or equivalent thereof in other tobacco products'. The determining of these Instruments finalises the investigation in relation to non-aneurysmal auric atherosclerotic disease as advertised in the Government Notices Gazette of 7 May 2019. These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 29 October 2019 concerning carotid arterial disease in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence in these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include: For RH SoP (Instrument No. 54/2020) adopting the latest revised Instrument format, which commenced in 2015; specifying a day of commencement for the Instrument in section 2; revising the name of the condition from 'carotid arterial disease' to 'carotid artery disease'; new definition of 'carotid artery disease' in subsection 7(2); revising ICD-10-AM codes for 'carotid artery disease' in subsection 7(3); revising the reference to 'ICD-10-AM code' in subsection 7(4); new factors in subsections 9(3) and 9(28) concerning being obese; revising the factors in subsections 9(3) and 9(29) concerning dyslipidaemia, by the inclusion of a note; new factors in subsections 9(5) and 9(30) concerning smoking of tobacco products, where smoking has permanently ceased; new factors in subsections 9(8) and 9(31) concerning exposure to second-hand smoke, where that exposure has not permanently ceased; new factors in subsections 9(8) and 9(33) concerning exposure to secon					
revising the definitions of 'dyslipidaemia', and 'relevant service' by the inclusion of a note in Schedule 1 - Dictionary; and deleting the definitions of 'hyperhomocysteinaemia' and 'pack-years of cigarettes, or equivalent thereof in other tobacco products'. The determining of these Instruments finalises the investigation in relation to non-aneurysmal audic atherosclerotic disease as advertised in the Government Notices Gazette of 7 May 2019. These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 29 October 2019 concerning carotid arterial disease in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence in has previously considered. The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include: For RH SoP (Instrument No. 54/2020) adopting the latest revised Instrument format, which commenced in 2015; specifying a day of commencement for the Instrument in section 2; revising the name of the condition from 'carotid arterial disease' to 'carotid artery disease'; new definition of 'carotid artery disease' in subsection 7(2); revising 1CD-10-AM codes for 'carotid artery disease' in subsection 7(3); revising the factors in subsections 9(3) and 9(28) concerning being obese; revising the factors in subsections 9(3) and 9(28) concerning smoking of tobacco products, where smoking has not permanently ceased; new factors in subsections 9(6) and 9(31) concerning smoking of tobacco products, where smoking has permanently ceased; new factors in subsections 9(8) and 9(32) concerning exposure to second-hand smoke, where that exposure has not permanently ceased; new factors in subsections 9(8) and 9(33) concerning exposure to second-hand smoke, where that exposure has not permanently ceased; new factors in subsections 9(8) and 9(33) concerning exposure to second-hand smoke, where that expo					
in Schedule 1 - Dictionary; and deleting the definitions of 'hyperhomocysteinaemia' and 'pack-years of cigarettes, or equivalent thereof in other tobacco products'. The determining of these Instruments finalises the investigation in relation to non-aneurysmal aortic atherosclerotic disease as advertised in the Government Notices Gazette of 7 May 2019. These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 29 October 2019 concerning carotid arterial disease in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence it has previously considered. The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include: For RH Sop (Instrument No. 54/2020) adopting the latest revised Instrument format, which commenced in 2015; specifying a day of commencement for the Instrument in section 2; revising the name of the condition from 'carotid arterial disease' to 'carotid artery disease'; new definition of 'carotid artery disease' in subsection 7(2); revising ICD-10-AM codes for 'carotid artery disease' in subsection 7(3); revising the factors in subsections 9(3) and 9(28) concerning being obese; revising the factors in subsections 9(4) and 9(29) concerning dyslipidaemia, by the inclusion of a note; new factors in subsections 9(5) and 9(30) concerning smoking of tobacco products, where smoking has not permanently ceased; new factors in subsections 9(7) and 9(31) concerning exposure to second-hand smoke, where that exposure has not permanently ceased; new factors in subsections 9(7) and 9(32) concerning exposure to second-hand smoke, where that exposure has permanently ceased; new factor in subsections 9(7) oncerning inability to undertake physical activity, for			· ·		
deleting the definitions of 'hyperhomocysteinaemia' and 'pack-years of cigarettes, or equivalent thereof in other tobacco products'. The determining of these Instruments finalises the investigation in relation to non-aneurysmal aortic atherosclerotic disease as advertised in the Government Notices Gazette of 7 May 2019. State					
equivalent thereof in other tobacco products'. The determining of these Instruments finalises the investigation in relation to non-ancurysmal aortic atherosclerotic disease as advertised in the Government Notices Gazette of 7 May 2019. These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 29 October 2019 concerning carotid arterial disease in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence in has previously considered. The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include: For RH SoP (Instrument No. 54/2020) adopting the latest revised Instrument format, which commenced in 2015; specifying a day of commencement for the Instrument in section 2; revising the name of the condition from 'carotid arterial disease' to 'carotid artery disease'; new definition of 'carotid artery disease' in subsection 7(2); revising ICD-10-AM codes for 'carotid artery disease' in subsection 7(3); revising the reference to 'ICD-10-AM code' in subsection 7(4); new factors in subsections 9(3) and 9(28) concerning being obese; revising the factors in subsections 9(4) and 9(29) concerning dyslipidaemia, by the inclusion of a note; new factors in subsections 9(5) and 9(30) concerning smoking of tobacco products, where smoking has not permanently ceased; new factors in subsections 9(6) and 9(31) concerning exposure to second-hand smoke, where that exposure has not permanently ceased; new factors in subsections 9(7) and 9(32) concerning exposure to second-hand smoke, where that exposure has permanently ceased; new factor in subsections 9(7) concerning inability to undertake physical activity, for			· ·		
aneurysmal aortic atherosclerotic disease as advertised in the Government Notices Gazette of 7 May 2019. These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 29 October 2019 concerning carotid arterial disease in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical- scientific evidence now available to the Authority, including the sound medical- scientific evidence in thas previously considered. The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instrument in section 2; expecifying a day of commencement for the Instrument in section 2; expecifying a day of commencement for the Instrument in section 2; expecifying a day of commencement for the Instrument in section 7(2); expecifying a day of commencement for the Instrument in section 7(3); expecifying a day of commencement for the Instrument in section 7(3); expecifying a day of commencement for the Instrument in section 7(3); expecifying a day of commencement for the Instrument in section 7(3); expecifying a day of commencement for the Instrument in section 7(3); expecifying a day of commencement for the Instrument in section 7(3); expecifying a the instrument of the condition from carotid artery disease' in subsection 7(3); expecifying the name of the condition from carotid artery disease' in subsection 7(4); expectively the factors in subsections 9(3) and 9(28) concerning belong obese; expectively the factors in subsections 9(3) and 9(29) concerning smoking of tobacco products, where smoking has not permanently ceased; enew factors in subsections 9(6) and 9(31) concerning exposure to second-hand smoke, where that exposure has not permanently ceased; enew factors in subsections 9(8) and 9(33) concerning exposure to second-hand smoke, where that exposure has permanently ceased; enew factor in subsections 9(8) oncerning inability to undertake physical activity, for					
Gazette of 7 May 2019. These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 29 October 2019 concerning carotid arterial disease in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered. The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include: For RH SoP (Instrument No. 54/2020) adopting the latest revised Instrument format, which commenced in 2015; specifying a day of commencement for the Instrument in section 2; revising the name of the condition from 'carotid arterial disease' to 'carotid artery disease'; new definition of 'carotid artery disease' in subsection 7(2); revising ICD-10-AM codes for 'carotid artery disease' in subsection 7(3); revising the reference to 'ICD-10-AM code' in subsection 7(4); new factors in subsections 9(3) and 9(28) concerning being obese; revising the factors in subsections 9(4) and 9(29) concerning dyslipidaemia, by the inclusion of a note; new factors in subsections 9(5) and 9(30) concerning smoking of tobacco products, where smoking has permanently ceased; new factors in subsections 9(6) and 9(31) concerning exposure to second-hand smoke, where that exposure has permanently ceased; new factors in subsections 9(8) and 9(33) concerning exposure to second-hand smoke, where that exposure has permanently ceased; new factors in subsections 9(8) and 9(33) concerning exposure to second-hand smoke, where that exposure has permanently ceased; new factors in subsections 9(8) and 9(33) concerning inability to undertake physical activity, for					
These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 29 October 2019 concerning carotid arterial disease in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered. The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include: For RH SoP (Instrument No. 54/2020) adopting the latest revised Instrument format, which commenced in 2015; specifying a day of commencement for the Instrument in section 2; revising the name of the condition from 'carotid arterial disease' to 'carotid artery disease'; new definition of 'carotid artery disease' in subsection 7(2); revising ICD-10-AM codes for 'carotid artery disease' in subsection 7(3); revising the reference to "ICD-10-AM code' in subsection 7(4); new factors in subsections 9(3) and 9(28) concerning being obese; revising the factors in subsections 9(4) and 9(29) concerning dyslipidaemia, by the inclusion of a note; new factors in subsections 9(5) and 9(30) concerning smoking of tobacco products, where smoking has not permanently ceased; new factors in subsections 9(6) and 9(31) concerning exposure to second-hand smoke, where that exposure has not permanently ceased; new factors in subsections 9(7) and 9(32) concerning exposure to second-hand smoke, where that exposure has permanently ceased; new factors in subsections 9(8) and 9(33) concerning exposure to second-hand smoke, where that exposure has permanently ceased; new factors in subsections 9(9) oncerning inability to undertake physical activity, for					
disease Notices Gazette of 29 October 2019 concerning carotid arterial disease in accordance with section 1960 of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered. The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include: For RH SoP (Instrument No. 54/2020) adopting the latest revised Instrument format, which commenced in 2015; specifying a day of commencement for the Instrument in section 2; revising the name of the condition from 'carotid arterial disease' to 'carotid artery disease'; new definition of 'carotid artery disease' in subsection 7(2); revising ICD-10-AM codes for 'carotid artery disease' in subsection 7(3); revising the reference to 'ICD-10-AM code' in subsection 7(4); new factors in subsections 9(3) and 9(28) concerning being obese; revising the factors in subsections 9(4) and 9(29) concerning dyslipidaemia, by the inclusion of a note; new factors in subsections 9(5) and 9(30) concerning smoking of tobacco products, where smoking has not permanently ceased; new factors in subsections 9(7) and 9(32) concerning exposure to second-hand smoke, where that exposure has not permanently ceased; new factors in subsections 9(8) and 9(33) concerning exposure to second-hand smoke, where that exposure has permanently ceased; new factor in subsections 9(8) and 9(33) concerning exposure to second-hand smoke, where that exposure has permanently ceased; new factor in subsections 9(10) concerning inability to undertake physical activity, for	5 A Q				
section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered. The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include: For RH SoP (Instrument No. 54/2020) adopting the latest revised Instrument format, which commenced in 2015; specifying a day of commencement for the Instrument in section 2; revising the name of the condition from 'carotid arterial disease' to 'carotid artery disease'; new definition of 'carotid artery disease' in subsection 7(2); revising ICD-10-AM codes for 'carotid artery disease' in subsection 7(3); revising the reference to 'ICD-10-AM code' in subsection 7(4); new factors in subsections 9(3) and 9(28) concerning being obese; revising the factors in subsections 9(4) and 9(29) concerning dyslipidaemia, by the inclusion of a note; new factors in subsections 9(5) and 9(30) concerning smoking of tobacco products, where smoking has not permanently ceased; new factors in subsections 9(6) and 9(31) concerning exposure to second-hand smoke, where that exposure has not permanently ceased; new factors in subsections 9(8) and 9(33) concerning exposure to second-hand smoke, where that exposure has not permanently ceased; new factors in subsections 9(8) and 9(33) concerning exposure to second-hand smoke, where that exposure has not permanently ceased; new factors in subsections 9(8) and 9(33) concerning exposure to second-hand smoke, where that exposure has permanently ceased; new factor in subsections 9(8) and 9(30) concerning inability to undertake physical activity, for		1			
evidence it has previously considered. The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include: For RH SoP (Instrument No. 54/2020) • adopting the latest revised Instrument format, which commenced in 2015; • specifying a day of commencement for the Instrument in section 2; • revising the name of the condition from 'carotid arterial disease' to 'carotid artery disease'; • new definition of 'carotid artery disease' in subsection 7(2); • revising ICD-10-AM codes for 'carotid artery disease' in subsection 7(3); • revising the reference to 'ICD-10-AM code' in subsection 7(4); • new factors in subsections 9(3) and 9(28) concerning being obese; • revising the factors in subsections 9(4) and 9(29) concerning dyslipidaemia, by the inclusion of a note; • new factors in subsections 9(5) and 9(30) concerning smoking of tobacco products, where smoking has not permanently ceased; • new factors in subsections 9(6) and 9(31) concerning smoking of tobacco products, where smoking has permanently ceased; • new factors in subsections 9(7) and 9(32) concerning exposure to second-hand smoke, where that exposure has not permanently ceased; • new factors in subsections 9(8) and 9(33) concerning exposure to second-hand smoke, where that exposure has permanently ceased; • new factors in subsections 9(8) and 9(33) concerning exposure to second-hand smoke, where that exposure has permanently ceased; • new factor in subsection 9(10) concerning inability to undertake physical activity, for					
The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include: For RH SoP (Instrument No. 54/2020) adopting the latest revised Instrument format, which commenced in 2015; specifying a day of commencement for the Instrument in section 2; revising the name of the condition from 'carotid arterial disease' to 'carotid artery disease'; new definition of 'carotid artery disease' in subsection 7(2); revising ICD-10-AM codes for 'carotid artery disease' in subsection 7(3); revising the reference to 'ICD-10-AM code' in subsection 7(4); new factors in subsections 9(3) and 9(28) concerning being obese; revising the factors in subsections 9(4) and 9(29) concerning dyslipidaemia, by the inclusion of a note; new factors in subsections 9(5) and 9(30) concerning smoking of tobacco products, where smoking has not permanently ceased; new factors in subsections 9(6) and 9(31) concerning smoking of tobacco products, where smoking has permanently ceased; new factors in subsections 9(7) and 9(32) concerning exposure to second-hand smoke, where that exposure has not permanently ceased; new factors in subsections 9(8) and 9(33) concerning exposure to second-hand smoke, where that exposure has permanently ceased; new factors in subsections 9(8) and 9(33) concerning exposure to second-hand smoke, where that exposure has permanently ceased; new factor in subsections 9(8) and 9(33) concerning exposure to second-hand smoke, where that exposure has permanently ceased;			scientific evidence now available to the Authority, including the sound medical-scientific		
these Instruments and the repealed Instruments, the differences include: For RH SoP (Instrument No. 54/2020) adopting the latest revised Instrument format, which commenced in 2015; specifying a day of commencement for the Instrument in section 2; revising the name of the condition from 'carotid arterial disease' to 'carotid artery disease'; new definition of 'carotid artery disease' in subsection 7(2); revising ICD-10-AM codes for 'carotid artery disease' in subsection 7(3); revising the reference to 'ICD-10-AM code' in subsection 7(4); new factors in subsections 9(3) and 9(28) concerning being obese; revising the factors in subsections 9(4) and 9(29) concerning dyslipidaemia, by the inclusion of a note; new factors in subsections 9(5) and 9(30) concerning smoking of tobacco products, where smoking has not permanently ceased; new factors in subsections 9(6) and 9(31) concerning smoking of tobacco products, where smoking has permanently ceased; new factors in subsections 9(7) and 9(32) concerning exposure to second-hand smoke, where that exposure has not permanently ceased; new factors in subsections 9(8) and 9(33) concerning exposure to second-hand smoke, where that exposure has permanently ceased; new factor in subsections 9(8) and 9(33) concerning exposure to second-hand smoke, where that exposure has permanently ceased;			evidence it has previously considered.		
For RH SoP (Instrument No. 54/2020) adopting the latest revised Instrument format, which commenced in 2015; specifying a day of commencement for the Instrument in section 2; revising the name of the condition from 'carotid arterial disease' to 'carotid artery disease'; new definition of 'carotid artery disease' in subsection 7(2); revising ICD-10-AM codes for 'carotid artery disease' in subsection 7(3); revising the reference to 'ICD-10-AM code' in subsection 7(4); new factors in subsections 9(3) and 9(28) concerning being obese; revising the factors in subsections 9(4) and 9(29) concerning dyslipidaemia, by the inclusion of a note; new factors in subsections 9(5) and 9(30) concerning smoking of tobacco products, where smoking has not permanently ceased; new factors in subsections 9(6) and 9(31) concerning smoking of tobacco products, where smoking has permanently ceased; new factors in subsections 9(7) and 9(32) concerning exposure to second-hand smoke, where that exposure has not permanently ceased; new factors in subsections 9(8) and 9(33) concerning exposure to second-hand smoke, where that exposure has permanently ceased; new factor in subsections 9(8) and 9(33) concerning exposure to second-hand smoke, where that exposure has permanently ceased;					
 adopting the latest revised Instrument format, which commenced in 2015; specifying a day of commencement for the Instrument in section 2; revising the name of the condition from 'carotid arterial disease' to 'carotid artery disease'; new definition of 'carotid artery disease' in subsection 7(2); revising ICD-10-AM codes for 'carotid artery disease' in subsection 7(3); revising the reference to 'ICD-10-AM code' in subsection 7(4); new factors in subsections 9(3) and 9(28) concerning being obese; revising the factors in subsections 9(4) and 9(29) concerning dyslipidaemia, by the inclusion of a note; new factors in subsections 9(5) and 9(30) concerning smoking of tobacco products, where smoking has not permanently ceased; new factors in subsections 9(6) and 9(31) concerning smoking of tobacco products, where smoking has permanently ceased; new factors in subsections 9(7) and 9(32) concerning exposure to second-hand smoke, where that exposure has not permanently ceased; new factors in subsections 9(8) and 9(33) concerning exposure to second-hand smoke, where that exposure has permanently ceased; new factor in subsections 9(8) and 9(33) concerning exposure to second-hand smoke, where that exposure has permanently ceased; new factor in subsection 9(10) concerning inability to undertake physical activity, for 					
 specifying a day of commencement for the Instrument in section 2; revising the name of the condition from 'carotid arterial disease' to 'carotid artery disease'; new definition of 'carotid artery disease' in subsection 7(2); revising ICD-10-AM codes for 'carotid artery disease' in subsection 7(3); revising the reference to 'ICD-10-AM code' in subsection 7(4); new factors in subsections 9(3) and 9(28) concerning being obese; revising the factors in subsections 9(4) and 9(29) concerning dyslipidaemia, by the inclusion of a note; new factors in subsections 9(5) and 9(30) concerning smoking of tobacco products, where smoking has not permanently ceased; new factors in subsections 9(6) and 9(31) concerning smoking of tobacco products, where smoking has permanently ceased; new factors in subsections 9(7) and 9(32) concerning exposure to second-hand smoke, where that exposure has not permanently ceased; new factors in subsections 9(8) and 9(33) concerning exposure to second-hand smoke, where that exposure has permanently ceased; new factor in subsection 9(10) concerning inability to undertake physical activity, for 			For RH SoP (Instrument No. 54/2020)		
 revising the name of the condition from 'carotid arterial disease' to 'carotid artery disease'; new definition of 'carotid artery disease' in subsection 7(2); revising ICD-10-AM codes for 'carotid artery disease' in subsection 7(3); revising the reference to 'ICD-10-AM code' in subsection 7(4); new factors in subsections 9(3) and 9(28) concerning being obese; revising the factors in subsections 9(4) and 9(29) concerning dyslipidaemia, by the inclusion of a note; new factors in subsections 9(5) and 9(30) concerning smoking of tobacco products, where smoking has not permanently ceased; new factors in subsections 9(6) and 9(31) concerning smoking of tobacco products, where smoking has permanently ceased; new factors in subsections 9(7) and 9(32) concerning exposure to second-hand smoke, where that exposure has not permanently ceased; new factors in subsections 9(8) and 9(33) concerning exposure to second-hand smoke, where that exposure has permanently ceased; new factor in subsection 9(10) concerning inability to undertake physical activity, for 					
 new definition of 'carotid artery disease' in subsection 7(2); revising ICD-10-AM codes for 'carotid artery disease' in subsection 7(3); revising the reference to 'ICD-10-AM code' in subsection 7(4); new factors in subsections 9(3) and 9(28) concerning being obese; revising the factors in subsections 9(4) and 9(29) concerning dyslipidaemia, by the inclusion of a note; new factors in subsections 9(5) and 9(30) concerning smoking of tobacco products, where smoking has not permanently ceased; new factors in subsections 9(6) and 9(31) concerning smoking of tobacco products, where smoking has permanently ceased; new factors in subsections 9(7) and 9(32) concerning exposure to second-hand smoke, where that exposure has not permanently ceased; new factors in subsections 9(8) and 9(33) concerning exposure to second-hand smoke, where that exposure has permanently ceased; new factor in subsections 9(8) and 9(33) concerning exposure to second-hand smoke, where that exposure has permanently ceased; new factor in subsection 9(10) concerning inability to undertake physical activity, for 					
 revising ICD-10-AM codes for 'carotid artery disease' in subsection 7(3); revising the reference to 'ICD-10-AM code' in subsection 7(4); new factors in subsections 9(3) and 9(28) concerning being obese; revising the factors in subsections 9(4) and 9(29) concerning dyslipidaemia, by the inclusion of a note; new factors in subsections 9(5) and 9(30) concerning smoking of tobacco products, where smoking has not permanently ceased; new factors in subsections 9(6) and 9(31) concerning smoking of tobacco products, where smoking has permanently ceased; new factors in subsections 9(7) and 9(32) concerning exposure to second-hand smoke, where that exposure has not permanently ceased; new factors in subsections 9(8) and 9(33) concerning exposure to second-hand smoke, where that exposure has permanently ceased; new factor in subsection 9(10) concerning inability to undertake physical activity, for 					
 revising the reference to 'ICD-10-AM code' in subsection 7(4); new factors in subsections 9(3) and 9(28) concerning being obese; revising the factors in subsections 9(4) and 9(29) concerning dyslipidaemia, by the inclusion of a note; new factors in subsections 9(5) and 9(30) concerning smoking of tobacco products, where smoking has not permanently ceased; new factors in subsections 9(6) and 9(31) concerning smoking of tobacco products, where smoking has permanently ceased; new factors in subsections 9(7) and 9(32) concerning exposure to second-hand smoke, where that exposure has not permanently ceased; new factors in subsections 9(8) and 9(33) concerning exposure to second-hand smoke, where that exposure has permanently ceased; new factor in subsection 9(10) concerning inability to undertake physical activity, for 					
 new factors in subsections 9(3) and 9(28) concerning being obese; revising the factors in subsections 9(4) and 9(29) concerning dyslipidaemia, by the inclusion of a note; new factors in subsections 9(5) and 9(30) concerning smoking of tobacco products, where smoking has not permanently ceased; new factors in subsections 9(6) and 9(31) concerning smoking of tobacco products, where smoking has permanently ceased; new factors in subsections 9(7) and 9(32) concerning exposure to second-hand smoke, where that exposure has not permanently ceased; new factors in subsections 9(8) and 9(33) concerning exposure to second-hand smoke, where that exposure has permanently ceased; new factor in subsection 9(10) concerning inability to undertake physical activity, for 					
 revising the factors in subsections 9(4) and 9(29) concerning dyslipidaemia, by the inclusion of a note; new factors in subsections 9(5) and 9(30) concerning smoking of tobacco products, where smoking has not permanently ceased; new factors in subsections 9(6) and 9(31) concerning smoking of tobacco products, where smoking has permanently ceased; new factors in subsections 9(7) and 9(32) concerning exposure to second-hand smoke, where that exposure has not permanently ceased; new factors in subsections 9(8) and 9(33) concerning exposure to second-hand smoke, where that exposure has permanently ceased; new factor in subsection 9(10) concerning inability to undertake physical activity, for 					
 new factors in subsections 9(5) and 9(30) concerning smoking of tobacco products, where smoking has not permanently ceased; new factors in subsections 9(6) and 9(31) concerning smoking of tobacco products, where smoking has permanently ceased; new factors in subsections 9(7) and 9(32) concerning exposure to second-hand smoke, where that exposure has not permanently ceased; new factors in subsections 9(8) and 9(33) concerning exposure to second-hand smoke, where that exposure has permanently ceased; new factor in subsection 9(10) concerning inability to undertake physical activity, for 					
 smoking has not permanently ceased; new factors in subsections 9(6) and 9(31) concerning smoking of tobacco products, where smoking has permanently ceased; new factors in subsections 9(7) and 9(32) concerning exposure to second-hand smoke, where that exposure has not permanently ceased; new factors in subsections 9(8) and 9(33) concerning exposure to second-hand smoke, where that exposure has permanently ceased; new factor in subsection 9(10) concerning inability to undertake physical activity, for 			· ·		
 new factors in subsections 9(6) and 9(31) concerning smoking of tobacco products, where smoking has permanently ceased; new factors in subsections 9(7) and 9(32) concerning exposure to second-hand smoke, where that exposure has not permanently ceased; new factors in subsections 9(8) and 9(33) concerning exposure to second-hand smoke, where that exposure has permanently ceased; new factor in subsection 9(10) concerning inability to undertake physical activity, for 					
 smoking has permanently ceased; new factors in subsections 9(7) and 9(32) concerning exposure to second-hand smoke, where that exposure has not permanently ceased; new factors in subsections 9(8) and 9(33) concerning exposure to second-hand smoke, where that exposure has permanently ceased; new factor in subsection 9(10) concerning inability to undertake physical activity, for 					
 new factors in subsections 9(7) and 9(32) concerning exposure to second-hand smoke, where that exposure has not permanently ceased; new factors in subsections 9(8) and 9(33) concerning exposure to second-hand smoke, where that exposure has permanently ceased; new factor in subsection 9(10) concerning inability to undertake physical activity, for 					
where that exposure has not permanently ceased; new factors in subsections 9(8) and 9(33) concerning exposure to second-hand smoke, where that exposure has permanently ceased; new factor in subsection 9(10) concerning inability to undertake physical activity, for					
 new factors in subsections 9(8) and 9(33) concerning exposure to second-hand smoke, where that exposure has permanently ceased; new factor in subsection 9(10) concerning inability to undertake physical activity, for 					
where that exposure has permanently ceased; • new factor in subsection 9(10) concerning inability to undertake physical activity, for					
			where that exposure has permanently ceased;		
<u>'</u>			cimical onset;		

SUMMARY OF CHANGES

- new factors in subsections 9(11) and 9(36) concerning chronic kidney disease;
- revising the factors in subsections 9(13) and 9(38) concerning receiving ionising radiation, by the inclusion of a note:
- new factors in subsections 9(14) and 9(39) concerning inability to consume fruit and vegetables;
- new factors in subsections 9(15) and 9(40) concerning infection with human immunodeficiency virus or hepatitis C virus;
- new factors in subsections 9(17) and 9(42) concerning infection of the affected artery with a bacterial or fungal organism;
- new factors in subsections 9(18) and 9(43) concerning autoimmune disease of the affected artery;
- revising the factors in subsections 9(20) and 9(45) concerning being exposed to arsenic, by the inclusion of a note;
- new factors in subsections 9(21) and 9(46) concerning obstructive sleep apnoea;
- revising the factors in subsections 9(22) and 9(47) concerning being postpartum, for dissection of the internal carotid artery only;
- revising the factors in subsections 9(23) and 9(48) concerning trauma to the affected segment of the artery, for aneurysm, dissection or arteriovenous fistula only;
- revising the factors in paragraphs 9(24)(a) and 9(49)(a) concerning trauma to the neck or the base of the skull, for dissection only;
- new factors in paragraphs 9(24)(b) and 9(49)(b) concerning taking a fluoroquinolone antibiotic, for dissection only;
- revising the factors in subsections 9(25) and 9(50) concerning taking a drug, for aneurysm or dissection of the common or internal carotid artery only;
- revising the factor in subsection 9(35) concerning inability to undertake physical activity, for clinical worsening;
- deleting the factors concerning smoking of cigarettes or the equivalent thereof in other tobacco products, as these are now covered by the factors in subsections 9(5) and 9(30) concerning smoking of tobacco products, where smoking has not permanently ceased and the factors in subsections 9(6) and 9(31) concerning smoking of tobacco products, where smoking has permanently ceased;
- deleting the factors concerning being in an atmosphere with a visible tobacco smoke haze
 in an enclosed space, as these are now covered by the factors in subsections 9(7) and 9(32)
 concerning exposure to second-hand smoke, where that exposure has not permanently
 ceased and the factors in subsections 9(8) and 9(33) concerning exposure to second-hand
 smoke, where that exposure has permanently ceased;
- deleting the factors concerning chronic renal disease, as these are now covered by the factors in subsections 9(11) and 9(36) concerning chronic kidney disease;
- deleting the factors concerning undergoing therapy with BCG vaccine, for aneurysm of the common, internal or external carotid artery only, as these are now covered by the factors in subsections 9(17) and 9(42) concerning infection of the affected artery with a bacterial or fungal organism;
- deleting the factors concerning having infective or noninfective vasculitis of the affected segment of the artery, as these are now covered by the factors in in subsections 9(15) and 9(40) concerning infection with human immunodeficiency virus or hepatitis C virus, the factors in subsections 9(17) and 9(42) concerning infection of the affected artery with a bacterial or fungal organism and the factors in subsections 9(18) and 9(43) concerning autoimmune disease of the affected artery;
- new definitions of 'abnormality of kidney structure or function', 'being exposed to second-hand smoke', 'being obese', 'BMI', 'chronic kidney disease', 'MRCA', 'pack-year of tobacco products', 'specified list of drugs' and 'VEA' in Schedule 1 Dictionary;
- revising the definitions of 'being exposed to arsenic as specified', 'dyslipidaemia', 'relevant service' by the inclusion of a note, 'trauma to the affected segment of the artery' and 'trauma to the neck or the base of the skull' in Schedule 1 Dictionary; and
- deleting the definitions of 'a 'a drug from the specified list', 'chronic renal disease', 'hyperhomocysteinaemia', 'pack-years of cigarettes, or the equivalent thereof in other tobacco products' and 'undergoing therapy with BCG vaccine'.

For BoP SoP (Instrument No. 55/2020)

- adopting the latest revised Instrument format, which commenced in 2015;
- specifying a date of effect for the Instrument in section 2;
- revising the name of the condition from 'carotid arterial disease' to 'carotid artery disease';
- new definition of 'carotid artery disease' in subsection 7(2);
- revising ICD-10-AM codes for 'carotid artery disease' in subsection 7(3);

SUMMARY OF CHANGES revising the reference to 'ICD-10-AM code' in subsection 7(4); revising the factors in subsections 9(3) and 9(22) concerning dyslipidaemia, by the inclusion of a note: new factors in subsections 9(4) and 9(23) concerning smoking of tobacco products, where smoking has not permanently ceased; new factors in subsections 9(5) and 9(24) concerning smoking of tobacco products, where smoking has permanently ceased; new factors in subsections 9(6) and 9(25) concerning exposure to second-hand smoke, where that exposure has not permanently ceased; new factors in subsections 9(7) and 9(26) concerning exposure to second-hand smoke, where that exposure has permanently ceased; new factors in subsections 9(9) and 9(28) concerning chronic kidney disease; revising the factors in subsections 9(11) and 9(30) concerning receiving ionising radiation, by the inclusion of a note; new factors in subsections 9(12) and 9(31) concerning infection with human immunodeficiency virus or hepatitis C virus; new factors in subsections 9(13) and 9(32) concerning infection of the affected artery with a bacterial or fungal organism; new factors in subsections 9(14) and 9(33) concerning autoimmune disease of the affected revising the factors in subsections 9(16) and 9(35) concerning being postpartum, for dissection of the internal carotid artery only; revising the factors in subsections 9(17) and 9(36) concerning trauma to the affected segment of the artery, for aneurysm, dissection or arteriovenous fistula only; revising the factors in subsections 9(18) and 9(37) concerning trauma to the neck or the base of the skull, for dissection only; revising the factors in subsections 9(19) and 9(38) concerning taking a drug, for aneurysm or dissection of the common or internal carotid artery only; deleting the factors concerning smoking of cigarettes or the equivalent thereof in other tobacco products, as these are now covered by the factors in subsections 9(4) and 9(23) concerning smoking of tobacco products, where smoking has not permanently ceased and the factors in subsections 9(5) and 9(24) concerning smoking of tobacco products, where smoking has permanently ceased; deleting the factors concerning chronic renal disease, as these are now covered by the factors in subsections 9(9) and 9(28) concerning chronic kidney disease; deleting the factors concerning undergoing therapy with BCG vaccine, for aneurysm of the common, internal or external carotid artery only, as these are now covered by the factors in subsections 9(13) and 9(32) concerning infection of the affected artery with a bacterial or fungal organism; deleting the factors concerning having infective or noninfective vasculitis of the affected segment of the artery, as these are now covered by the factors in subsections 9(12) and 9(31) concerning infection with human immunodeficiency virus or hepatitis C virus, the factors in subsections 9(13) and 9(32) concerning infection of the affected artery with a bacterial or fungal organism and the factors in subsections 9(14) and 9(33) concerning autoimmune disease of the affected artery; new definitions of 'abnormality of kidney structure or function', 'being exposed to secondhand smoke', 'chronic kidney disease', 'MRCA', 'pack-year of tobacco products', 'specified list of drugs' and 'VEA' in Schedule 1 - Dictionary; revising the definitions of 'dyslipidaemia', 'relevant service' by the inclusion of a note, 'trauma to the affected segment of the artery' and 'trauma to the neck or the base of the skull' in Schedule 1 - Dictionary; and deleting the definitions of 'a drug from the specified list', 'chronic renal disease', 'hyperhomocysteinaemia', ' pack-years of cigarettes, or the equivalent thereof in other tobacco products' and 'undergoing therapy with BCG vaccine'. The determining of these Instruments finalises the investigation in relation to carotid arterial disease as advertised in the Government Notices Gazette of 29 October 2019. These Instruments result from an investigation notified by the Authority in the Government 56 & renal artery Notices Gazette of 6 November 2018 concerning renal artery atherosclerotic disease in 57/2020 atherosclerotic disease accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medicalscientific evidence it has previously considered. The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:

For RH SoP (Instrument No. 56/2020)

- adopting the latest revised Instrument format, which commenced in 2015;
- specifying a day of commencement for the Instrument in section 2;
- revising the definition of 'renal artery atherosclerotic disease' in subsection 7(2);
- revising the reference to 'ICD-10-AM code' in subsection 7(4);
- new factors in subsections 9(3) and 9(18) concerning being obese;
- revising the factors in subsections 9(4) and 9(19) concerning dyslipidaemia, by the inclusion of a note;
- new factors in subsections 9(5) and 9(20) concerning smoking of tobacco products, where smoking has not permanently ceased;
- new factors in subsections 9(6) and 9(21) concerning smoking of tobacco products, where smoking has permanently ceased:
- new factors in subsections 9(7) and 9(22) concerning exposure to second-hand smoke, where that exposure has not permanently ceased;
- new factors in subsections 9(8) and 9(23) concerning exposure to second-hand smoke, where that exposure has permanently ceased;
- new factors in subsections 9(10) and 9(25) concerning inability to undertake physical activity;
- new factors in subsections 9(11) and 9(26) concerning chronic kidney disease;
- revising the factors in subsections 9(13) and 9(28) concerning receiving ionising radiation, by the inclusion of a note;
- new factors in subsections 9(14) and 9(29) concerning inability to consume fruit and vegetables;
- new factors in subsections 9(15) and 9(30) concerning periodontitis;
- revising the factor in subsection 9(31) concerning being treated with an angiotensin converting enzyme inhibitor or an angiotensin receptor blocker, for clinical worsening only;
- deleting the factors concerning smoking of cigarettes or the equivalent thereof in other tobacco products, as these are now covered by the factors in subsections 9(5) and 9(20) concerning smoking of tobacco products, where smoking has not permanently ceased and the factors in subsections 9(6) and 9(21) concerning smoking of tobacco products, where smoking has permanently ceased;
- new definitions of 'abnormality of kidney structure or function', 'being exposed to second-hand smoke', 'being obese', 'BMI', 'chronic kidney disease', 'MET', 'MRCA', 'pack-year of tobacco products' and 'VEA' in
- Schedule 1 Dictionary:
- revising the definitions of 'dyslipidaemia' and 'relevant service' by the inclusion of a note, in Schedule 1 - Dictionary; and
- deleting the definitions of 'a course of therapeutic radiation', 'hyperhomocysteinaemia' and 'pack-years of cigarettes, or the equivalent thereof in other tobacco products'.

For BoP SoP (Instrument No. 57/2020)

- adopting the latest revised Instrument format, which commenced in 2015;
- specifying a date of effect for the Instrument in section 2;
- revising the definition of 'renal artery atherosclerotic disease' in subsection 7(2);
- revising the reference to 'ICD-10-AM code' in subsection 7(4);
- revising the factors in subsections 9(3) and 9(13) concerning dyslipidaemia, by the inclusion of a note;
- new factors in subsections 9(4) and 9(14) concerning smoking of tobacco products, where smoking has not permanently ceased;
- new factors in subsections 9(5) and 9(15) concerning smoking of tobacco products, where smoking has permanently ceased;
- new factors in subsections 9(6) and 9(16) concerning exposure to second-hand smoke, where that exposure has not permanently ceased;
- new factors in subsections 9(7) and 9(17) concerning exposure to second-hand smoke, where that exposure has permanently ceased;
- revising the factors in subsections 9(10) and 9(20) concerning receiving ionising radiation, by the inclusion of a note;
- revising the factor in subsection 9(21) concerning treatment with with an angiotensin converting enzyme inhibitor or an angiotensin receptor blocker, for clinical worsening only;
- deleting the factors concerning smoking of cigarettes or the equivalent thereof in other tobacco products, as these are now covered by the factors in subsections 9(4) and 9(14) concerning smoking of tobacco products, where smoking has not permanently ceased and the factors in subsections 9(5) and 9(15) concerning smoking of tobacco products, where smoking has permanently ceased;

SUMMARY OF CHANGES new definitions of 'being exposed to second-hand smoke', 'MRCA', 'pack-year of tobacco products' and 'VEA' in Schedule 1 - Dictionary; revising the definitions of 'dyslipidaemia', and 'relevant service' by the inclusion of a note, in Schedule 1 - Dictionary; and deleting the definitions of 'a course of therapeutic radiation', 'hyperhomocysteinaemia', and 'pack-years of cigarettes, or the equivalent thereof in other tobacco products'. The determining of these Instruments finalises the investigation in relation to renal artery atherosclerotic disease as advertised in the Government Notices Gazette of 6 November 2018. 58 & aplastic anaemia These Instruments result from an investigation notified by the Authority in the Government 59/2020 Notices Gazette of 29 October 2019 concerning aplastic anaemia in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered. The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include: For RH SoP (Instrument No. 58/2020) adopting the latest revised Instrument format, which commenced in 2015; specifying a day of commencement for the Instrument in section 2; revising the definition of 'aplastic anaemia' in subsection 7(2); revising ICD-10-AM codes for 'aplastic anaemia' in subsection 7(3); revising the reference to 'ICD-10-AM code' in subsection 7(4); revising the factor in subsection 9(2) concerning being treated with a drug specified in the Schedule 2 - Drugs, for clinical onset only; new factor in subsection 9(3) concerning being treated with a drug, for clinical onset only; revising the factor in subsection 9(4) concerning being treated with a non-aspirin, nonsteroidal, anti-inflammatory drug, for clinical onset only; revising the factor in subsection 9(6) concerning being exposed to benzene, for clinical onset only; new factor in subsection 9(7) concerning inhaling, ingesting or having cutaneous contact with a herbicide or insecticide, for clinical onset only; revising the factor in subsection 9(8) concerning acute hepatitis, for clinical onset only; revising the factor in subsection 9(10) concerning autoimmune diseases, for clinical onset new factor in subsection 9(11) concerning haematological malignancies, for clinical onset revising the factor in subsection 9(12) concerning thymoma or thymic carcinoma, for clinical onset only: new factor in subsection 9(13) concerning infection with parvovirus B19 or acute infectious mononucleosis, for clinical onset only; new factor in subsection 9(14) concerning being pregnant, for clinical worsening; deleting the factor concerning inhaling, ingesting or having cutaneous contact with a pesticide, as this is now covered by the factor in subsection 9(7) concerning inhaling, ingesting or having cutaneous contact with a herbicide or insecticide; deleting the factor concerning undergoing a course of therapeutic radiation for ankylosing spondylitis; new definitions of 'MRCA', 'specified list of haematological malignancies', 'specified list of herbicides and insecticides' and 'VEA' in Schedule 1 - Dictionary; revising the definitions of 'being exposed to benzene as specified', 'relevant service' by the inclusion of a note and 'specified list of autoimmune diseases' in Schedule 1 - Dictionary; new table of specified drugs in Schedule 2 - Drugs; and deleting the definitions of 'a drug or a drug from a class of drugs from the specified list', 'a nonsteroidal anti-inflammatory drug from the specified list', 'inhaling, ingesting or having cutaneous contact with' and 'specified list of pesticides'. For BoP SoP (Instrument No. 59/2020) adopting the latest revised Instrument format, which commenced in 2015; specifying a day of commencement for the Instrument in section 2; revising the definition of 'aplastic anaemia' in subsection 7(2); revising ICD-10-AM codes for 'aplastic anaemia' in subsection 7(3); revising the reference to 'ICD-10-AM code' in subsection 7(4);

SUMMARY OF CHANGES				
SUMMAR	Y OF CHANGES	 revising the factor in subsection 9(2) concerning being treated with a drug specified in the Schedule 2 - Drugs, for clinical onset only; new factor in subsection 9(3) concerning being treated with a drug, for clinical onset only; revising the factor in subsection 9(4) concerning being exposed to benzene, for clinical onset only; new factor in subsection 9(5) concerning inhaling, ingesting or having cutaneous contact with an organophosphate insecticide, for clinical onset only; revising the factor in subsection 9(6) concerning acute hepatitis, for clinical onset only; revising the factor in subsection 9(8) concerning autoimmune diseases, for clinical onset only; new factor in subsection 9(9) concerning lymphocytic leukaemia/small lymphocytic lymphoma or T-cell large granular lymphocytic leukaemia, for clinical onset only; revising the factor in subsection 9(10) concerning thymoma or thymic carcinoma, for clinical onset only; new factor in subsection 9(11) concerning being pregnant, for clinical worsening; deleting the factor concerning undergoing a course of therapeutic radiation for ankylosing spondylitis; new definitions of 'MRCA' and 'VEA', in Schedule 1 - Dictionary; revising the definitions of being exposed to benzene as specified', 'relevant service' by the inclusion of a note and 'specified list of autoimmune diseases' in Schedule 1 - Dictionary; new table of specified drugs in Schedule 2 - Drugs; and deleting the definition of 'a drug or a drug from a class of drugs from the specified list'. On 16 April 2020, the Authority wrote to organisations representing veterans, service personnel and their dependants regarding the proposed Instrument and the medical-scientific material considered by the Authority. This letter emphasised the deletion of the factor relating to undergoing a course of therapeutic radiation for ankylosing spondylitis within the six months before the cli		
60 & 61/2020	pure red cell aplasia	The determining of these Instruments finalises the investigation in relation to aplastic anaemia as advertised in the Government Notices Gazette of 29 October 2019. These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 29 October 2019 concerning aplastic anaemia in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence available to the Authority. On consideration of the sound medical-scientific evidence the Authority decided to determine separate Statements of Principles for aplastic anaemia and pure red cell aplasia. The available evidence for pure red cell aplasia supports a number of risk factors being causally associated with the clinical onset and worsening of this disease. The evidence also indicates that red cell aplasia is a separate disease from aplastic anaemia, with a different pathogenesis in the bone marrow.		
		The determining of these Instruments finalises the investigation in relation to aplastic anaemia as advertised in the Government Notices Gazette of 29 October 2019.		
62 & 63/2020	chloracne	These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 7 May 2019 concerning <i>chloracne</i> in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.		
		 For RH SoP (Instrument No. 62/2020) adopting the latest revised Instrument format, which commenced in 2015; specifying a day of commencement for the Instrument in section 2; revising the definition of 'chloracne' in subsection 7(2); revising the factors in subsections 9(1) and 9(2) concerning inhaling, ingesting or having cutaneous contact with a polyhalogenated aromatic hydrocarbon; deleting the factors concerning inhaling, ingesting or having cutaneous contact with a polychlorodibenzofuran (PCDF), as these are now covered by the factors in subsections 9(1) and 9(2) concerning inhaling, ingesting or having cutaneous contact with a polyhalogenated aromatic hydrocarbon; deleting the factors concerning inhaling, ingesting or having cutaneous contact with a polychlorodibenzo-para-dioxin (PCDD), as these are now covered by the factors in 		

SUMMARY OF CHANGES subsections 9(1) and 9(2) concerning inhaling, ingesting or having cutaneous contact with a polyhalogenated aromatic hydrocarbon; deleting the factors concerning inhaling, ingesting or having cutaneous contact with a specified chemical agent, as these are now covered by the factors in subsections 9(1) and 9(2) concerning inhaling, ingesting or having cutaneous contact with a polyhalogenated aromatic hydrocarbon; deleting the factors concerning inhaling, ingesting or having cutaneous contact with dihydrotrifluoromethylphenyl benzothiopyranopyrazolone; new definitions of 'MRCA', 'polychlorodibenzofurans (PCDFs) as specified', 'polychlorodibenzo-para-dioxins (PCDDs) as specified', 'specified list of polyhalogenated aromatic hydrocarbons' and 'VEA' in Schedule 1 - Dictionary; revising the definition of 'relevant service' by the inclusion of a note, in Schedule 1 -Dictionary; and deleting the definitions of 'a polychlorodibenzofuran (PCDF) from the specified list', 'a polychlorodibenzo-para-dioxin (PCDD) from the specified list', 'a polyhalogenated aromatic hydrocarbon from the specified list', 'a specified chemical agent' and 'inhaling, ingesting or having cutaneous contact with'. For BoP SoP (Instrument No. 63/2020) adopting the latest revised Instrument format, which commenced in 2015; specifying a day of commencement for the Instrument in section 2; revising the definition of 'chloracne' in subsection 7(2); revising the factors in subsections 9(1) and 9(2) concerning inhaling, ingesting or having cutaneous contact with a polyhalogenated aromatic hydrocarbon; deleting the factors concerning inhaling, ingesting or having cutaneous contact with a polychlorodibenzofuran (PCDF), as these are now covered by the factors in subsections 9(1) and 9(2) concerning inhaling, ingesting or having cutaneous contact with a polyhalogenated aromatic hydrocarbon; deleting the factors concerning inhaling, ingesting or having cutaneous contact with a polychlorodibenzo-para-dioxin (PCDD), as these are now covered by the factors in subsections 9(1) and 9(2) concerning inhaling, ingesting or having cutaneous contact with a polyhalogenated aromatic hydrocarbon; deleting the factors concerning inhaling, ingesting or having cutaneous contact with a specified chemical agent, as these are now covered by the factors in subsections 9(1) and 9(2) concerning inhaling, ingesting or having cutaneous contact with a polyhalogenated aromatic hydrocarbon; new definitions of 'MRCA', 'polychlorodibenzofurans (PCDFs) as specified', 'polychlorodibenzo-para-dioxins (PCDDs) as specified', 'specified list of polyhalogenated aromatic hydrocarbons' and 'VEA' in Schedule 1 - Dictionary; revising the definition of 'relevant service' by the inclusion of a note, in Schedule 1 -Dictionary: and deleting the definitions of 'a polychlorodibenzofuran (PCDF) from the specified list', 'a polychlorodibenzo-para-dioxin (PCDD) from the specified list', 'a polyhalogenated aromatic hydrocarbon from the specified list', 'a specified chemical agent' and 'inhaling, ingesting or having cutaneous contact with'. On 16 April 2020, the Authority wrote to organisations representing veterans, service personnel and their dependants regarding the proposed Instrument and the medical-scientific material considered by the Authority. This letter emphasised the deletion of factors relating to *inhaling*. ingesting or having cutaneous contact with dihydrotrifluoromethylphenyl benzothiopyranopyrazolone from the reasonable hypothesis Statement of Principles. The Authority provided an opportunity to the organisations to make representations in relation to the proposed Instrument prior to its determination. No submissions were received for consideration by the Authority. Non-substantial changes were made to the proposed Instrument following this consultation process. The determining of these Instruments finalises the investigation in relation to chloracne as advertised in the Government Notices Gazette of 7 May 2019. 64 & These Instruments result from an investigation notified by the Authority in the Government chronic pancreatitis 65/2020 Notices Gazette of 6 November 2018 concerning chronic pancreatitis in accordance with section 196G of the VEA. The investigation involved an examination of the sound medicalscientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered. The contents of these Instruments are in similar terms as the repealed Instruments. Comparing

these Instruments and the repealed Instruments, the differences include:

SUMMARY OF CHANGES For RH SoP (Instrument No. 64/2020) adopting the latest revised Instrument format, which commenced in 2015; specifying a day of commencement for the Instrument in section 2; revising the definition of 'chronic pancreatitis' in subsection 7(2); revising the reference to 'ICD-10-AM code' in subsection 7(4); revising the factor in subsection 9(1) concerning smoking of tobacco products, for clinical onset only; revising the factor in subsection 9(2) concerning consumption of alcohol, for clinical onset revising the factor in subsection 9(3) concerning undergoing therapeutic radiation for cancer, for clinical onset only; revising the factor in subsection 9(7) concerning hypertriglyceridaemia, for clinical onset revising the factor in subsection 9(9) concerning chronic renal failure, for clinical onset deleting the factor concerning receiving ionising radiation; new definitions of 'chronic renal failure', 'MRCA', 'pack-year of tobacco products' and 'VEA' in Schedule 1 - Dictionary; revising the definition of 'relevant service' by the inclusion of a note in Schedule 1 -Dictionary; and deleting the definitions of 'a course of therapeutic radiation', 'cumulative equivalent dose' and 'pack-years of cigarettes, or the equivalent thereof in other tobacco products'. For BoP SoP (Instrument No. 65/2020) adopting the latest revised Instrument format, which commenced in 2015; specifying a day of commencement for the Instrument in section 2; revising the definition of 'chronic pancreatitis' in subsection 7(2); revising the reference to 'ICD-10-AM code' in subsection 7(4); revising the factor in subsection 9(1) concerning smoking of tobacco products, for clinical onset only: revising the factor in subsection 9(2) concerning consumption of alcohol, for clinical onset revising the factor in subsection 9(3) concerning undergoing therapeutic radiation for cancer, for clinical onset only; revising the factor in subsection 9(7) concerning hypertriglyceridaemia, for clinical onset only; deleting the factor concerning receiving ionising radiation; new definitions of 'MRCA', 'pack-year of tobacco products' and 'VEA' in Schedule 1 -Dictionary: revising the definition of 'relevant service' by the inclusion of a note in Schedule 1 -Dictionary; and deleting the definitions of 'a course of therapeutic radiation', 'cumulative equivalent dose' and 'pack-years of cigarettes, or the equivalent thereof in other tobacco products'. On 16 April 2020, the Authority wrote to organisations representing veterans, service personnel and their dependants regarding the proposed Instrument and the medical-scientific material considered by the Authority. This letter emphasised the deletion of the factor relating to having received a cumulative equivalent dose of at least 10 sieverts of ionising radiation to the pancreas, at least one year before the clinical onset of chronic pancreatitis. The Authority provided an opportunity to the organisations to make representations in relation to the proposed Instrument prior to its determination. No submissions were received for consideration by the Authority. Non-substantial changes were made to the proposed Instrument following this consultation process The determining of these Instruments finalises the investigation in relation to *chronic* pancreatitis as advertised in the Government Notices Gazette of 6 November 2018. 66 & malignant neoplasm These Instruments result from an investigation notified by the Authority in the Government 67/2020 of bone and Notices Gazette of 6 November 2018 concerning malignant neoplasm of bone and articular articular cartilage cartilage in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered. The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include: For RH SoP (Instrument No. 66/2020)

SUMMARY OF CHANGES adopting the latest revised Instrument format, which commenced in 2015; specifying a day of commencement for the Instrument in section 2: revising the definition of 'malignant neoplasm of bone and articular cartilage' in subsection 7(2); revising the reference to 'ICD-10-AM code' in subsection 7(4); revising the factor in subsection 9(1) concerning receiving ionising radiation, by the inclusion of a note, for clinical onset only; revising the factor in subsection 9(2) concerning Paget's disease of bone, for clinical onset new factor in subsection 9(3) concerning osteonecrosis of the metaphysis or diaphysis of bone, for clinical onset only; revising the factor in subsection 9(4) concerning chronic osteomyelitis, for clinical onset new factor in subsection 9(5) concerning giant cell tumour of bone, for clinical onset only; revising the factor in subsection 9(6) concerning stem cell or bone marrow transplantation, for clinical onset only; new factor in subsection 9(7) concerning taking growth hormone, for clinical onset only; new factor in subsection 9(8) concerning taking an anthracycline chemotherapeutic agent, for clinical onset only; new factor in subsection 9(9) concerning taking denosumab, for clinical onset only; deleting the factor concerning bone infarct, as this is now covered by the factor in subsection 9(3) concerning osteonecrosis of the metaphysis or diaphysis of bone; new definitions of 'MRCA' and 'VEA' in Schedule 1 - Dictionary; and revising the definition of 'relevant service' by the inclusion of a note in Schedule 1 -Dictionary. For BoP SoP (Instrument No. 67/2020) adopting the latest revised Instrument format, which commenced in 2015; specifying a day of commencement for the Instrument in section 2; revising the definition of 'malignant neoplasm of bone and articular cartilage' in subsection 7(2); revising the reference to 'ICD-10-AM code' in subsection 7(4); revising the factor in subsection 9(1) concerning receiving ionising radiation, by the inclusion of a note, for clinical onset only; revising the factor in subsection 9(2) concerning Paget's disease of bone, for clinical onset only; revising the factor in subsection 9(3) concerning chronic osteomyelitis, for clinical onset new factor in subsection 9(4) concerning giant cell tumour of bone, for clinical onset only; new factor in subsection 9(5) concerning taking an anthracycline chemotherapeutic agent, for clinical onset only; new definitions of 'MRCA' and 'VEA' in Schedule 1 - Dictionary; and revising the definition of 'relevant service' by the inclusion of a note in Schedule 1 -Dictionary. The determining of these Instruments finalises the investigation in relation to malignant neoplasm of bone and articular cartilage as advertised in the Government Notices Gazette of 6 November 2018. 68 & Amendment trochanteric bursitis and gluteal 69/2020 These instruments amend Statements of Principles Nos. 45 & 46 of 2015 concerning tendinopathy trochanteric bursitis and gluteal tendinopathy by: For RH SoP (Instrument No. 68/2020) revising factors (h) and (p) in clause 6 concerning significant disturbance of normal gait; deleting the definition of 'a significant disturbance of normal gait' in clause 9. For BoP SoP (Instrument No. 69/2020) inserting new factors (ga) and (na) in clause 6 concerning significant disturbance of normal gait. The determining of these Instruments finalises the investigation in relation to trochanteric bursitis and gluteal tendinopathy as advertised in the Government Notices Gazette of 18 June 2020.